Melatonin and melatonergic drugs on sleep: Possible mechanisms of action

International Journal of Neuroscience

Volumn 119, Issue 6, 2009, Pages 821-846

  Srinivasan, Venkataramanujan ^a   Pandi Perumal, Seithikurippu R ^b   Trahkt, Ilya ^b   Spence, D Warren ^c   Poeggeler, Burkhard ^d   Hardeland, Ruediger ^d   Cardinali, Daniel P ^e  

^a SRM INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

^b College of Physicians and Surgeons of Columbia University ^*  (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Agomelatine; Circadin; Hypnotics; Insomnia; Melatonin; Ramelteon; Sleep; Suprachiasmatic nucleus

Indexed keywords

AGOMELATINE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; RAMELTEON; ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT; HYPNOTIC SEDATIVE AGENT; INDENE DERIVATIVE; MELATONIN RECEPTOR;

CAT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; HUMAN; INSOMNIA; META ANALYSIS; MONKEY; MONOTHERAPY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RAT; REM SLEEP; REVIEW; SLEEP; SLEEP WAKING CYCLE; SUPRACHIASMATIC NUCLEUS; SYSTEMATIC REVIEW; AGING; ANIMAL; BIOSYNTHESIS; CIRCADIAN RHYTHM; DEPRESSION; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ACETAMIDES; AGING; ANIMALS; ANTIDEPRESSIVE AGENTS; CIRCADIAN RHYTHM; DEPRESSIVE DISORDER; HUMANS; HYPNOTICS AND SEDATIVES; INDENES; MELATONIN; RECEPTORS, MELATONIN; SIGNAL TRANSDUCTION; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUPRACHIASMATIC NUCLEUS;

EID: 65649123794     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.1080/00207450802328607     Document Type: Review

References (115)

1. Arendt, J. (2006). Melatonin and human rhythms. Chronobiology International, 23, 21-37.
2. Arendt, J. & Skene, D. J. (2005). Melatonin as a chronobiotic. Sleep Medicine Reviews, 9, 25-39.
3. Attenburrow, M. E., Cowen, P. J., & Sharpley, A. L. (1996). Low dose melatonin improves sleep in healthy middle-aged subjects. Psychopharmacology (Berl), 126, 179-181.
4. Axelrod, J. (1974). The pineal gland: A neurochemical transducer. Science, 184, 1341-1348.
5. Balzamo, E., Santucci, V., Seri, B., Vuillon-Cacciuttolo, G., & Bert, J. (1977). Nonhuman primates: Laboratory animals of choice for neurophysiologic studies of sleep. Laboratory Animal Science, 27, 879-886.
6. Bellipanni, G., Di Marzo, F., Blasi, F., & Di Marzo, A. (2005). Effects of melatonin in perimenopausal and menopausal women: Our personal experience. Annals of the New York Academy of Sciences, 1057, 393-402.
7. Bellon, A. (2006). Searching for new options for treating insomnia: Are melatonin and ramelteon beneficial? Journal of Psychiatric Practice, 12, 229-243.
8. Berson, D. M., Dunn, F. A., & Takao, M. (2002). Phototransduction by retinal ganglion cells that set the circadian clock. Science, 295, 1070-1073.
9. Brydon, L., Roka, F., Petit, L., de Coppet, P., Tissot, M., Barrett, P., et al. (1999). Dual signaling of human Mel1a melatonin receptors via Gi2, Gi3 and Gq/11 proteins. Molecular Endocrinology, 13, 2025-2038.
10. Brzezinski, A., Vangel, M. G., Wurtman, R. J., Norrie, G., Zhdanova, I., Ben Shushan, A., et al. (2005). Effects of exogenous melatonin on sleep: A meta-analysis. Sleep Medicine Reviews, 9, 41-50.
11. Buscemi, N., Vandermeer, B., Hooton, N., Pandya, R., Tjosvold, L., Hartling, L., et al. (2006). Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: Meta-analysis. BritishMedical Journal, 332, 385-393.
12. Buysse, D. J., Nofzinger, E. A., Germain, A., Meltzer, C. C., Wood, A., Ombao, H., et al. (2004). Regional brain glucose metabolism during morning and evening wakefulness in humans: Preliminary findings. Sleep, 27, 1245-1254.
13. Cajochen, C., Krauchi, K., Mori, D., Graw, P., &Wirz-Justice, A. (1997).Melatonin and S-20098 increase REM sleep and wake-up propensity without modifying NREM sleep homeostasis. American Journal of Physiology, 272, R1189-R1196.
14. Cardinali, D. P. & Pevet, P. (1998). Basic aspects of melatonin action. Sleep Medicine Review, 2, 175-190.
15. Cricco, M., Simonsick, E. M., & Foley, D. J. (2001). The impact of insomnia on cognitive functioning in older adults. Journal of the American Geriatric Society, 49, 1185-1189.
16. Dardente, H., Klosen, P., Caldelas, I., Pevet, P., & Masson-Pevet, M. (2002). Phenotype of Per1- and Per2-expressing neurons in the suprachiasmatic nucleus of a diurnal rodent (Arvicanthis ansorgei): Comparison with a nocturnal species, the rat. Cell and Tissue Research, 310, 85-92.
17. Deboer, T., Vansteensel, M. J., Detari, L., & Meijer, J. H. (2003). Sleep states alter activity of suprachiasmatic nucleus neurons. Nature Neuroscience, 6, 1086-1090.
18. Dollins, A. B., Zhdanova, I. V., Wurtman, R. J., Lynch, H. J., & Deng, M. H. (1994). Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proceedings of theNational Academies of Sciences USA, 91, 1824-1828.
19. Dubocovich, M. L. (2006). Agomelatine targets a range of major depressive disorder symptoms. Current Opinion in Investigational Drugs, 7, 670-680.
20. Dubocovich, M. L., Cardinali, D. P., Delagrange, P., Krause, D. N., Strosberg, D., Sugden, D., et al. (2000). Melatonin receptors. In IUPHAR (ed.), The IUPHAR Compendium of Receptor Characterization and Clasification, 2nd. ed. London: IUPHAR Media, 271-277.
21. Dubocovich, M. L., Yun, K., Al Ghoul, W. M., Benloucif, S., & Masana, M. I. (1998). Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB Journal, 12, 1211-1220.
22. Duffy, J. F., Zeitzer, J. M., Rimmer, D. W., Klerman, E. B., Dijk, D. J., & Czeisler, C. A. (2002). Peak of circadian melatonin rhythm occurs later within the sleep of older subjects. American Journal of Physiology. Endocrinology and Metabolism, 282, E297-E303.
23. Ebisawa, T., Karne, S., Lerner, M. R., & Reppert, S.M. (1994). Expression cloning of a high-affinity melatonin receptor from Xenopus dermal melanophores. Proceedings of the National Academies of Sciences USA, 91, 6133-6137.
24. Edgar, D. M., Dement, W. C., & Fuller, C. A. (1993). Effect of SCN lesions on sleep in squirrel monkeys: Evidence for opponent processes in sleep-wake regulation. Journal of Neuroscience, 13, 1065-1079.
25. Egger, S. S., Bachmann, A., Hubmann, N., Schlienger, R. G., & Krahenbuhl, S. (2006). Prevalence of potentially inappropriate medication use in elderly patients: Comparison between general medical and geriatric wards. Drugs and Aging, 23, 823-837.
26. Erman, M., Seiden, D., Zammit, G., Sainati, S., & Zhang, J. (2006). An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Medicine, 7, 17-24.
27. Ferry, G., Ubeaud, C., Lambert, P. H., Bertin, S., Coge, F., Chomarat, P., et al. (2005).Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: Investigations with both indoleamine 2, 3-dioxygenase and myeloperoxidase. Biochemical Journal, 388, 205-215.
28. France, C. P., Weltman, R. H., Koek, W., Cruz, C. M., & McMahon, L. R. (2006). Acute and chronic effects of ramelteon in Rhesus monkeys (Macaca mulatta): Dependence liability studies. Behavioral Neuroscience, 120, 535-541.
29. Fuller, P. M., Gooley, J. J., & Saper, C. B. (2006). Neurobiology of the sleep-wake cycle: Sleep architecture, circadian regulation, and regulatory feedback. Journal of Biological Rhythms, 21, 482-493.
30. Ganguly, S., Weller, J. L., Ho, A., Chemineau, P., Malpaux, B., & Klein, D. C. (2005). Melatonin synthesis: 14-3-3-dependent activation and inhibition of arylalkylamine N-acetyltransferase mediated by phosphoserine-205. Proceedings of the National Academies of Sciences USA, 102, 1222-1227.
31. Garfinkel, D., Laudon, M., Nof, D., & Zisapel, N. (1995). Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet, 346, 541-544.
32. Gastel, J. A., Roseboom, P. H., Rinaldi, P. A., Weller, J. L., & Klein, D. C. (1998). Melatonin production: Proteasomal proteolysis in serotonin N-acetyltransferase regulation. Science, 279, 1358-1360.
33. Gauer, F., Masson-Pevet, M., Stehle, J., &Pevet, P. (1994). Daily variations in melatonin receptor density of rat pars tuberalis and suprachiasmatic nuclei are distinctly regulated. Brain Research, 641, 92-98.
34. Godson, C.&Reppert, S.M. (1997). The Mel1a melatonin receptor is coupled to parallel signal transduction pathways. Endocrinology, 138, 397-404.
35. Goldstein, R. & Pavel, S. (1981). REM sleep suppression in cats by melatonin. Brain Research Bulletin, 7, 723-724.
36. Golombek, D. A., Pevet, P., & Cardinali, D. P. (1996). Melatonin effect on behavior: Possiblemediation by the centralGABAergic system. Neuroscience Biobehavioral Reviews, 20, 403-412.
37. Gorfine, T., Assaf, Y., Goshen-Gottstein, Y., Yeshurun, Y., & Zisapel, N. (2006). Sleepanticipating effects of melatonin in the human brain. Neuroimage, 31, 410-418.
38. Greenblatt, D. J., Harmatz, J. S., & Karim, A. (2007). Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. Journal of Clinical Pharmacology, 47, 485-496.
39. Guilleminault, C. (2005). Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder. European Neuropsychopharmacology, 15(Suppl. 3), S419.
40. Haimov, I., Laudon, M., Zisapel, N., Souroujon, M., Nof, D., Shlitner, A., et al. (1994). Sleep disorders and melatonin rhythms in elderly people. British Medical Journal, 309, 167.
41. Hunt, A. E., Al Ghoul, W. M., Gillette, M. U., & Dubocovich, M. L. (2001). Activation of MT2 melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. American Journal of Physiology. Cell Physiology, 280, C110-C118.
42. Ibata, Y., Okamura, H., Tanaka, M., Tamada, Y., Hayashi, S., Iijima, N., et al. (1999). Functional morphology of the suprachiasmatic nucleus. Frontiers in Neuroendocrinology, 20, 241-268.
43. Iguchi, H., Kato, K. I., & Ibayashi, H. (1982). Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis. Journal of Clinical Endocrinology and Metabolism, 54, 1025-1027.
44. Kalsbeek, A., Perreau-Lenz, S., & Buijs, R.M. (2006). A network of (autonomic) clock outputs. Chronobiology International, 23, 521-535. (Pubitemid 43879802)
45. Karim, A., Tolbert, D., &Cao, C. (2006).Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. Journal of Clinical Pharmacology, 46, 140-148.
46. Kato, K., Hirai, K., Nishiyama, K., Uchikawa, O., Fukatsu, K., Ohkawa, S., et al. (2005). Neurochemical properties of ramelteon (TAK-375), a selectiveMT1/MT2 receptor agonist. Neuropharmacology, 48, 301-310.
47. Klein, D. C. & Moore, R. Y. (1979). Pineal N-acetyltransferase and hydroxyindole-Omethyltransferase: Control by the retinohypothalamic tract and the suprachiasmatic nucleus. Brain Research, 174, 245-262.
48. Lagarde, D. & Milhaud, C. (1990). Electroencephalographic effects of modafinil, an alpha-1-adrenergic psychostimulant, on the sleep of rhesus monkeys. Sleep, 13, 441-448.
49. Lam, R. W. (2006). Sleep disturbances and depression: a challenge for antidepressants. International Clinical Psychopharmacology, 21(Suppl. 1), S25-S29.
50. Lavie, P. (1986). Ultrashort sleep-waking schedule. III. "Gates" and "forbidden zones" for sleep. Electroencephalography and Clinical Neurophysiology, 63, 414-425.
51. Lee, H. S., Billings, H. J., & Lehman, M. N. (2003). The suprachiasmatic nucleus: A clock of multiple components. Journal of Biological Rhythms, 18, 435-449.
52. Leger, D., Laudon, M., & Zisapel, N. (2004). Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. American Journal of Medicine, 116, 91-95.
53. Lemoine, P., Nir, T., Laudon, M., & Zisapel, N. (2007). Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. Journal of Sleep Research, 16, 362-380.
54. Lerner, A. B., Case, J. D., Takahashi, Y., Lee, T. H., & Mori, N. (1958). Isolation of melatonin, a pineal factor that lightens melanocytes. Journal of the American Chemical Society, 80, 2587.
55. Lewy, A. J. (1999). Melatonin as a marker and phase-resetter of circadian rhythms in humans. Advances in Experimental Medicine and Biology, 460, 425-434.
56. Liu, C., Weaver, D. R., Jin, X., Shearman, L. P., Pieschl, R. L., Gribkoff, V. K., et al. (1997). Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron, 19, 91-102.
57. Lopes, M. C., Quera-Salva, M. A., & Guilleminault, C. (2005). Cycling alternating pattern in the NREM sleep of patients within major depressive disorder: Baseline results and change overtime with a new antidepressant. Sleep Medicine, 6(Suppl. 2), 87-88.
58. Lopez-Burillo, S., Tan, D. X., Mayo, J. C., Sainz, R. M., Manchester, L. C., & Reiter, R. J. (2003). Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and alpha-lipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: A study of their individual and synergistic actions. Journal of Pineal Research, 34, 269-277.
59. Marczynski, T. J., Yamaguchi, N., Ling, G. M., & Grodzinska, L. (1964). Sleep induced by the administration of melatonin (5-methoxy- acetyltryptamine) to the hypothalamus in unrestrained cats. Experientia, 20, 435-437.
60. Maronde, E. & Stehle, J. H. (2007). The mammalian pineal gland: Known facts, unknown facets. Trends in Endocrinology and Metabolism, 18, 142-149.
61. Masana, M. I., Benloucif, S., & Dubocovich, M. L. (2000). Circadian rhythm of MT1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse. Journal of Pineal Research, 28, 185-192.
62. McArthur, A. J., Hunt, A. E., &Gillette, M.U. (1997).Melatonin action and signal transduction in the rat suprachiasmatic circadian clock: Activation of protein kinase C at dusk and dawn. Endocrinology, 138, 627-634.
63. Mendelson, W. B. (2002). Melatonin microinjection into the medial preoptic area increases sleep in the rat. Life Sciences, 71, 2067-2070.
64. Miyamoto, M., Nishikawa, H., Doken, Y., Hirai, K., Uchikawa, O., & Ohkawa, S. (2004). The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep, 27, 1319-1325. (Pubitemid 44138898)
65. Monti, J. M., Alvarino, F., Cardinali, D. P., Savio, I., & Pintos, A. (1999). Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia. Archives of Gerontology and Geriatrics, 28, 85-98.
66. Moore, R. Y. (1996). Neural control of the pineal gland. Behavioral Brain Research, 73, 125-130.
67. Nosjean, O., Ferro, M., Coge, F., Beauverger, P., Henlin, J. M., Lefoulon, F., et al. (2000). Identification of the melatonin-binding site MT3 as the quinone reductase 2. Journal of Biological Chemistry, 275, 31311-31317.
68. Pandi-Perumal, S. R., Seils, L. K., Kayumov, L., Ralph, M. R., Lowe, A., Moller, H., et al. (2002). Senescence, sleep, and circadian rhythms. Ageing Research Reviews, 1, 559-604.
69. Pandi-Perumal, S. R., Srinivasan, V., Cardinali, D. P., & Monti, M. J. (2006a). Could agomelatine be the ideal antidepressant? Expert Reviews in Neurotherapeutics, 6, 1595-1608.
70. Pandi-Perumal, S. R., Srinivasan, V., Maestroni, G. J. M., Cardinali, D. P., Poeggeler, B., &Hardeland, R. (2006b).Melatonin: Nature's most versatile biological signal? FEBS Journal, 273, 2813-2838.
71. Pandi-Perumal, S. R., Srinivasan, V., Poeggeler, B., Hardeland, R., & Cardinali, D. P. (2007). Drug insight: The use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nature Clinical Practice Neurology, 3(4), 221-228.
72. Pandi-Perumal, S. R., Zisapel, N., Srinivasan, V., & Cardinali, D. P. (2005). Melatonin and sleep in aging population. Experimental Gerontology, 40, 911-925.
73. Pevet, P., Bothorel, B., Slotten, H., &Saboureau, M. (2002). The chronobiotic properties of melatonin. Cell and Tissue Research, 309, 183-191.
74. Poirel, V. J., Masson-Pevet, M., Pevet, P., & Gauer, F. (2002). MT1 melatonin receptor mRNA expression exhibits a circadian variation in the rat suprachiasmatic nuclei. Brain Research, 946, 64-71.
75. Quera-Salva, M. A., Vanier, B., & Chapotot, F. (2005). Effect of agomelatine on the sleep EEG in patients with major depressive disorders (MDD). European Neuropsychopharmacology, 15(Suppl. 3), S435.
76. Rajaratnam, S. M., Dijk, D. J., Middleton, B., Stone, B. M., & Arendt, J. (2003). Melatonin phase-shifts human circadian rhythms with no evidence of changes in the duration of endogenous melatonin secretion or the 24-hour production of reproductive hormones. Journal of Clinical Endocrinology and Metabolism, 88, 4303-4309.
77. Reghunandanan, V. & Reghunandanan, R. (2006). Neurotransmitters of the suprachiasmatic nuclei. Journal of Circadian Rhythms, 4, 2.
78. Reppert, S. M., Godson, C., Mahle, C. D., Weaver, D. R., Slaugenhaupt, S. A., & Gusella, J. F. (1995). Molecular characterization of a second melatonin receptor expressed in human retina and brain: The Mel1b melatonin receptor. Proceedings of the National Academies of Sciences USA, 92, 8734-8738.
79. Reppert, S. M., Weaver, D. R., & Ebisawa, T. (1994). Cloning and characterization of a mammalianmelatonin receptor thatmediates reproductive and circadian responses. Neuron, 13, 1177-1185.
80. Reppert, S.M., Weaver, D.R., Ebisawa, T., Mahle, C.D., &Kolakowski, L. F., Jr. (1996). Cloning of a melatonin-related receptor from human pituitary. FEBS Letters, 386, 219-224.
81. Roka, F., Brydon, L., Waldhoer, M., Strosberg, A. D., Freissmuth, M., Jockers, R., et al. (1999). Tight association of the human Mel1a-melatonin receptor and Gi: Precoupling and constitutive activity. Molecular Pharmacology, 56, 1014-1024.
82. Rosen, J., Than, N. N., Koch, D., Poeggeler, B., Laatsch, H., & Hardeland, R. (2006). Interactions of melatonin and its metabolites with the ABTS cation radical: Extension of the radical scavenger cascade and formation of a novel class of oxidation products, C2-substituted 3-indolinones. Journal of Pineal Research, 41, 374-381.
83. Roth, T., Seiden, D., Sainati, S., Wang-Weigand, S., Zhang, J., & Zee, P. (2006). Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Medicine, 7, 312-318.
84. Roth, T., Stubbs, C., & Walsh, J. K. (2005). Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep, 28, 303-307.
85. Sack, R. L., Lewy, A. J., Erb, D. L., Vollmer, W. M., & Singer, C. M. (1986). Human melatonin production decreases with age. Journal of Pineal Research, 3, 379-388.
86. Saper, C. B., Scammell, T. E., & Lu, J. (2005). Hypothalamic regulation of sleep and circadian rhythms. Nature, 437, 1257-1263. (Pubitemid 41568665)
87. Schomerus, C. & Korf, H. W. (2005). Mechanisms regulating melatonin synthesis in the mammalian pineal organ. Annals of the New York Academy of Sciences, 1057, 372-383.
88. Srinivasan, V., Smits, M., Spence, W., Lowe, A. D., Kayumov, L., Pandi-Perumal, S. R., et al. (2006).Melatonin in mood disorders.World Journal of Biological Psychiatry, 7, 138-151.
89. Srinivasan, V., Spence, D. W., Pandi-Perumal, S. R., Trakht, I., & Cardinali, D. P. (2008). Jet lag: Therapeutic use ofmelatonin and possible application ofmelatonin analogues. Travel Medicine and Infectious Disease, 6, 17-28.
90. Stephan, F. K. & Zucker, I. (1972). Rat drinking rhythms: Central visual pathways and endocrine factors mediating responsiveness to environmental illumination. Physiology and Behavior, 8, 315-326.
91. Tan, D. X., Manchester, L. C., Terron, M. P., Flores, L. J., & Reiter, R. J. (2007). One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? Journal of Pineal Research, 42, 28-42.
92. Tozawa, T., Mishima, K., Satoh, K., Echizenya, M., Shimizu, T., &Hishikawa, Y. (2003). Stability of sleep timing against the melatonin secretion rhythm with advancing age: Clinical implications. Journal of Clinical Endocrinology and Metabolism, 88, 4689-4695.
93. Turek, F.W.&Gillette, M.U. (2004).Melatonin, sleep, and circadian rhythms:Rationale for development of specific melatonin agonists. Sleep Medicine, 5, 523-532.
94. Tzischinsky, O., Shlitner, A., & Lavie, P. (1993). The association between the nocturnal sleep gate and nocturnal onset of urinary 6-sulfatoxymelatonin. Journal of Biological Rhythms, 8, 199-209.
95. van den Top, M., Buijs, R. M., Ruijter, J. M., Delagrange, P., Spanswick, D., & Hermes, M. L. (2001). Melatonin generates an outward potassium current in rat suprachiasmatic nucleus neurones in vitro independent of their circadian rhythm. Neuroscience, 107, 99-108.
96. Van Someren, E. J. (2000). Circadian and sleep disturbances in the elderly. Experimental Gerontology, 35, 1229-1237.
97. Vgontzas, A.N.&Kales, A. (1999). Sleep and its disorders. Annual Review of Medicine, 50, 387-400.
98. Viswanathan, N. & Davis, F. C. (1997). Single prenatal injections of melatonin or the D1-dopamine receptor agonist SKF 38393 to pregnant hamsters sets the offsprings' circadian rhythms to phases 180 degrees apart. Journal of Comparative Physiology [A], 180, 339-346.
99. von Gall, C., Stehle, J. H., & Weaver, D. R. (2002). Mammalian melatonin receptors: Molecular biology and signal transduction. Cell and Tissue Research, 309, 151-162.
100. Wade, A. G., Ford, I., Crawford, G., MaMahon, A. D., Nir, T., Laudon, M., et al. (2007). Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: Quality of sleep and next-day alertness outcomes. Current Medical Research and Opinion, 23, 2597-2605. (Pubitemid 350033462)
101. Wauquier, A. (1993). Aging and changes in phasic events during sleep. Physiology and Behavior, 54, 803-806.
102. Wurtman, R. J. & Zhdanova, I. (1995). Improvement of sleep quality by melatonin. Lancet, 346, 1491.
103. Wyatt, J. K., Ritz-de Cecco, A., Czeisler, C. A., & Dijk, D. J. (1999). Circadian temperature and melatonin rhythms, sleep, and neurobehavioral function in humans living on a 20-h day. American Journal of Physiology, 277, R1152-R1163.
104. Ying, S. W., Rusak, B., Delagrange, P., Mocaer, E., Renard, P., & Guardiola-Lemaitre, B. (1996).Melatonin analogues as agonists and antagonists in the circadian system and other brain areas. European Journal of Pharmacology, 296, 33-42.
105. Yoon, I. Y., Kripke, D. F., Elliott, J. A., Youngstedt, S. D., Rex, K. M., & Hauger, R. L. (2003). Age-related changes of circadian rhythms and sleep-wake cycles. Journal of the American Geriatric Society, 51, 1085-1091.
106. Yukuhiro, N., Kimura, H., Nishikawa, H., Ohkawa, S., Yoshikubo, S., & Miyamoto, M. (2004). Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Research, 1027, 59-66. (Pubitemid 39370995)
107. Zee, P. C. & Manthena, P. (2007). The brain's master circadian clock: implications and opportunities for therapy of sleep disorders. Sleep Medicine Review, 11, 59-70.
108. Zhdanova, I. V. (2005).Melatonin as a hypnotic: Pro. Sleep Medicine Review, 9, 51-65.
109. Zhdanova, I. V., Cantor, M. L., Leclair, O. U., Kartashov, A. I., &Wurtman, R. J. (1998). Behavioral effects of melatonin treatment in non-human primates. Sleep Research Online, 1, 114-118.
110. Zhdanova, I. V. & Giorgetti, M. (2002). Melatonin alters behavior and cAMP levels in nucleus accumbens induced by cocaine treatment. Brain Research, 956, 323-331.
111. Zhdanova, I. V., Wurtman, R. J., Lynch, H. J., Ives, J. R., Dollins, A. B., Morabito, C., et al. (1995). Sleep-inducing effects of low doses of melatonin ingested in the evening. Clinical Pharmacology and Therapeutics, 57, 552-558.
112. Zhdanova, I. V., Wurtman, R. J., Morabito, C., Piotrovska, V. R., & Lynch, H. J. (1996). Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep, 19, 423-431.
113. Zisapel, N. (2001). Melatonin-dopamine interactions: From basic neurochemistry to a clinical setting. Cell Molecular Neurobiology, 21, 605-616.
114. Zisapel, N. (2007). Sleep and sleep disturbances: Biological basis and clinical implications. Cellular and Molecular Life Sciences, 64, 1174-1186.
115. Zupancic, M. & Guilleminault, C. (2006). Agomelatine: A preliminary review of a new antidepressant. CNS Drugs, 20, 981-992.